Cancer Research Institute
Clinical Trials
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.
The purposes of this study are to: • Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib. • Determine whether KO-2806 has an antitumor effect (reduces the size of your tumor ...
LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
This study is currently enrolling.
The main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of LY3537982, by itself or in co ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Study Title for Study Participants: Pediatric MATCH screening protocol
This study is currently enrolling.
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that target those changes. This combination of a tumor with a mutation and a drug that aims at that muta ...
NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)
This study is currently enrolling.
The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following ...
NG-641-01: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
This study is currently enrolling.
The purpose of this research study is to find out the following: (1) What effects, good and/or bad, treatment with NG-641 has on you and your cancer; (2) The amount of NG-641 that can be given and/or the best timing between dos ...
NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA
This study is currently enrolling.
This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...
Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
This study is currently enrolling.
Phase 1 study of NG-641 plus nivolumab in metastatic or advanced epithelial tumours
This study is currently enrolling.
The purpose of this research study is to find out the effects, good and/or bad, treatment with the study drug and nivolumab has on you and your cancer and to find out what happens to the study drug and the proteins it makes in ...
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC
This study is currently enrolling.
This study will explore the safety and the efficacy (how well it works) of an investigational drug talazoparib, when added to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).